Post-Frey recovery · live window 7/10 → 8/1 · canonical IF returns ~Aug 1
Eighteen changes were made to this protocol in twenty-four hours. Nearly all were subtractions, deferrals, or tests — safe directions. But attribution is collapsing. Everything else in the next three weeks is measurement, not modification. If something goes wrong on 7/20, you need to be able to say why.
Acetaminophen — documented adverse, VM July 2026 · NSAIDs — ulcer / GI-bleed history · Soy — stops Creon working (SerinAid PS is the exception: lecithin lipid fraction, no trypsin inhibitors) · Potassium supplements — as of 7/9, on the ARB
Dark or tarry stool · visible blood · new dizziness · resting HR climbing · fever or rigors · any BP reading ≥180/120 → urgent care, not a message
The regimen produces atypically suppressed inflammatory markers. WBC 4.2, globulin 1.5, CRP low. Clinical suspicion outweighs standard lab thresholds when assessing acute infection, cholangitis, or pancreatitis flare. A normal white count does not exclude infection in this patient.
Three adversarial passes lodged zero findings against the chronic core. Not one of the ~40 compounds was faulted on evidence quality, dose, timing, interaction, or sourcing — outside the post-surgical window. The auditor hunted hepatotoxicity, nephrotoxicity, immunosuppression, and antiplatelet burden, and returned with in-vitro signals and no human bleeding data.
The record: GMI 5.7–5.8% across 180 days · zero readings above 250 · eGFR 113 · normal hepatic function despite an obstruction history · HbA1c 6.1% in T3c diabetes, without insulin.
What was miscalibrated was the perioperative overlay, the instruments, and some of the reasoning. All three sit around the regimen. None sit in it.